Beyond the Right to Exclude: Why Large Companies Obtain Patents They May Never Assert

Executive Summary: Large companies obtain patents not only to exclude competitors, but also to influence commercial decisions long before litigation occurs. A strategically constructed portfolio can deter operating competitors through a form of mutually assured destruction, provide bargaining currency for cross-licenses, preserve future product options, control competitive design space, strengthen relationships with suppliers and partners, support standards participation, generate licensing revenue, and increase leverage in financing and corporate transactions. Patents also serve informational and reputational functions by signaling technological capability, recognizing inventors, organizing institutional knowledge, and supporting marketing claims directed to investors, customers, recruits, and national or regional stakeholders. These benefits depend less on raw portfolio size than on claim quality, commercial relevance, ownership, geographic coverage, and alignment with the intended audience or counterparty. Patent-based marketing additionally requires disciplined methodology because application counts, issued patents, patent families, acquired assets, and territorial filings measure different things. Effective portfolio governance therefore assigns each patent family an identifiable business function, tests whether patent protection is superior to alternatives such as trade secrecy or defensive publication, and periodically reevaluates whether the expected strategic benefit continues to justify the cost.

I.                   Introduction: The Patent That Is Never Asserted

A corporate patent department periodically confronts an awkward question: why continue paying to obtain and maintain a patent that the company does not expect to assert? The conventional answer—that a patent protects an invention—is correct but incomplete. Many patents are valuable because of what they cause other companies, investors, customers, employees, and transaction partners to do before anyone files a complaint. A patent may discourage a competitor from suing, improve the terms of a cross-license, preserve an undeveloped product option, support an acquisition price, strengthen a standards position, or give an investor-relations team evidence for a claim of technological leadership. None of those uses requires a final judgment of infringement.

The empirical evidence has long reflected that broader corporate reality. A landmark survey of 1,478 U.S. manufacturing research-and-development laboratories found that firms patented for reasons extending well beyond commercializing or licensing the patented invention. For product innovations, 82% of respondents identified blocking rival patents as a reason to patent, 59% identified preventing infringement suits, and 48% identified enhancing reputation; only 28% identified licensing revenue. Patent-intensive firms were disproportionately concerned with negotiations and preventing suits. Wesley M. Cohen, Richard R. Nelson & John P. Walsh, Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not), NBER Working Paper No. 7552, at 18, 24, 37 (2000). Later work likewise identified defensive blocking, bargaining, reputation, and internal incentives as distinct motives for patenting. Knut Blind et al., Motives to Patent: Empirical Evidence from Germany, 35 Res. Pol’y 655, 658–66 (2006).

Calling those motives “non-statutory” does not mean that they are legally unconnected to the patent. They are not additional rights supplied by the Patent Act. They are business consequences that can arise because the company owns a potentially valid, enforceable, transferable, and territorially defined right to exclude. The statutory right is the foundation; corporate strategy determines how that foundation is used.

That distinction matters to portfolio governance. If the only acceptable return were damages or royalties, most corporate portfolios would look irrational. If patents are instead treated as corporate decision assets, the relevant inquiry changes. The question is not merely whether a patent will be asserted. It is whether owning the patent changes the company’s competitive or commercial position enough to justify its cost.

II.                The Legal Baseline: What a Patent Does—and Does Not—Provide

The Patent Act grants a patentee the right to exclude others from making, using, offering to sell, selling, or importing the claimed invention in the United States. 35 U.S.C. § 154(a)(1). It does not grant an affirmative right to practice the invention. Bio-Tech. Gen. Corp. v. Genentech, Inc., 80 F.3d 1553, 1559 (Fed. Cir. 1996); see also Deepsouth Packing Co. v. Laitram Corp., 406 U.S. 518, 526 (1972). A company can own a patent on an improvement and still infringe an earlier, broader patent by commercializing that improvement. Conversely, a company may be free to sell a product even though it owns no patent covering the product. Patent ownership and freedom to operate answer different questions.

The formal right is also claim-specific, territorial, and time-limited. Its practical force depends on claim scope, validity, enforceability, remaining term, evidence of infringement, the relevant jurisdiction, and the available remedy. Even after proving infringement, a patent owner does not receive an injunction automatically; it must satisfy the traditional equitable test. eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388, 391–94 (2006). Those limitations explain why raw patent totals are a poor substitute for portfolio analysis.

An individual patent and a portfolio nevertheless operate differently. A single patent may cover one claimed architecture. A coordinated portfolio can cover a core platform, improvements, alternative implementations, manufacturing methods, interfaces, deployment models, and commercially important use cases. It can also distribute risk: the loss or narrow construction of one patent need not eliminate the company’s entire position. The economic and strategic value of a portfolio can therefore exceed the sum of the expected litigation value of each patent considered separately. Gideon Parchomovsky & R. Polk Wagner, Patent Portfolios, 154 U. Pa. L. Rev. 1, 5–14 (2005).

That portfolio effect is the bridge between the Patent Act and the reasons large companies actually file. The legal right remains exclusion. The business uses include deterrence, exchange, signaling, financing, collaboration, optionality, and marketing.

III.             Defensive Deterrence and Litigation Leverage

A.                 Deterring Suits by Operating Competitors

 Large companies frequently participate in markets where a single product practices hundreds or thousands of potentially patentable features. In those “complex product” industries, no participant can confidently assume that it owns every right needed to make the finished product. A substantial portfolio can therefore create mutual exposure: a competitor considering an infringement suit must also consider whether its own products, services, or manufacturing processes read on the target’s patents.

The resulting dynamic resembles “mutually assured destruction.” Each company may possess patent “missiles”—issued claims directed toward commercially important aspects of the other company’s operations. Their principal value may lie in remaining unfired. If Company A asserts a patent, Company B may respond with counterclaims against Company A’s principal products or revenue streams. Both companies then face litigation expense, intrusive discovery, potential damages, possible requests for injunctive relief, and uncertainty affecting customers and supply chains. The prospect of escalation may induce both sides to exercise restraint, negotiate a cross-license, or resolve a dispute without litigation.

The analogy does not mean that enforcement would literally destroy either company. Rather, it describes a credible capacity to impose costs and business disruption that may exceed the value of the initiating claim. A defensive portfolio provides a form of “second-strike” capability: even if the company does not intend to sue first, it retains patents that can be asserted if a competitor initiates hostilities. Deterrence is strongest when the competitor knows—or can readily determine—that those patents map onto products or services it cannot easily discontinue or redesign.

This defensive value lies in the prospect of retaliation or reciprocal licensing, not necessarily in a plan to assert the patents affirmatively. That is consistent with empirical evidence that companies in complex-product industries use patents disproportionately to force negotiations and prevent infringement suits. Cohen, Nelson & Walsh, supra, at 19–24. It also helps explain the “patent paradox” observed in the semiconductor industry, where firms increased patenting to reduce holdup risk and accumulate bargaining currency even though patents were often considered imperfect tools for appropriating returns from individual inventions. Bronwyn H. Hall & Rosemarie Ham Ziedonis, The Patent Paradox Revisited: An Empirical Study of Patenting in the U.S. Semiconductor Industry, 1979–1995, 32 RAND J. Econ. 101, 103–08, 125–26 (2001).

Mutually assured destruction does not require numerical parity. A thousand narrow patents covering obsolete internal processes may provide less deterrence than ten well-drafted patents that map onto a competitor’s current revenue. The credibility of a patent “missile” depends on claim scope, validity, remaining term, geographic coverage, detectability of infringement, available evidence, and the commercial importance of the accused activity. A patent aimed at a competitor’s flagship product may have substantially greater deterrent value than hundreds of patents with no identifiable commercial target.

The metaphor also has an important legal limit. “Aiming” a patent at a competitor does not mean appropriating the competitor’s invention. The patent must arise from the named inventors’ work and satisfy the applicable statutory requirements. In this context, aiming means identifying the company’s own patentable advances, drafting claims that cover foreseeable competing implementations, and maintaining the resulting rights where they can create credible defensive leverage. Portfolio size may open the conversation; target relevance and claim quality determine whether the deterrent is believable.

B.                 Creating Currency for Cross-Licensing

Where both companies own relevant patents, a dispute can end in a cross-license rather than an injunction. Each side receives access to some or all of the other’s portfolio, and any balancing payment can reflect the parties’ relative positions. The patents function as bargaining currency.

Corporate announcements make that purpose explicit. When Samsung and Google announced a broad cross-license covering existing patents and patents filed during the following decade, they described the arrangement as giving each company access to the other’s portfolio, reducing potential litigation, and supporting deeper research collaboration. Samsung Elecs., Samsung and Google Sign Global Patent License Agreement (Jan. 27, 2014), https://news.samsung.com/global/samsung-and-google-sign-global-patent-license-agreement. Cisco and Samsung similarly stated that their cross-license was intended to promote innovation and “freedom of operation.” Samsung Elecs., Cisco and Samsung Enter into Patent Cross-License Agreement (Feb. 6, 2014), https://news.samsung.com/global/cisco-and-samsung-enter-into-patent-cross-license-agreement.

“Freedom of operation” in that commercial sense should not be confused with a legal opinion that no third-party patent is infringed. A bilateral cross-license addresses the parties’ rights as defined by the agreement. It does not clear unrelated patents held by others.

C.                 The Nonpracticing-Entity Limitation

Defensive deterrence works best against an operating company with products or processes that can be accused of infringement. It is less effective against an entity whose business is patent assertion and that makes no potentially infringing product. That is a practical inference from the acts that constitute direct infringement, not a categorical rule about every nonpracticing entity. See 35 U.S.C. § 271(a). The Federal Trade Commission’s study of patent assertion entities distinguished portfolio-licensing models from litigation-focused models and documented licensing practices in which the asserted patents were acquired from other owners. Fed. Trade Comm’n, Patent Assertion Entity Activity: An FTC Study 3–4, 15–17 (2016). The reduced ability to answer an assertion with product-based patent counterclaims is an important limit on the “mutually assured destruction” account of corporate portfolios.

Large-company disclosures recognize both sides of that reality. IBM’s 2025 Form 10-K states that its portfolio may not prevent competing offerings, may not adequately deter misuse, and does not ensure access to licenses the company may need; it separately identifies aggressive enforcement by third parties, including nonpracticing entities, as a risk. International Business Machines Corp., Annual Report (Form 10-K) 4 (Feb. 24, 2026). A portfolio can improve a company’s position without eliminating patent risk.

IV.            Preserving Strategic Optionality

A.                 Protecting Products That Do Not Yet Exist

Research often precedes a business decision. Engineers may solve a problem before management knows whether the company will commercialize the solution, license it, contribute it to a standard, use it in a partnership, or abandon it. Filing preserves a legal option while those decisions mature.

Delay can make the option irreversible. A disclosure, public use, placement on sale, or other public availability may trigger 35 U.S.C. § 102(a)(1), subject to the limited inventor-originated exceptions in § 102(b)(1), and many foreign systems do not provide the same grace period. A U.S. nonprovisional application ordinarily publishes eighteen months after the earliest filing date for which priority is claimed, subject to § 122(b)’s exceptions. 35 U.S.C. § 122(b)(1)(A). Filing therefore requires a deliberate choice: accept eventual disclosure in exchange for the possibility of exclusivity, or rely on secrecy when the information can realistically remain secret.

The option is bounded by the disclosure actually filed. Continuation practice permits later claims that are entitled to the earlier application’s benefit only when the statutory requirements are satisfied. 35 U.S.C. § 120. A company cannot use a continuation years later to claim technical matter that the original application did not adequately describe. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1348–52 (Fed. Cir. 2010) (en banc). Preserving optionality therefore depends on an original disclosure broad enough to support foreseeable commercial paths without becoming untethered from what the inventors actually possessed.

V.               Controlling Competitive Design Space

A.                 Protecting the Design Space, Not Merely the Launch Product

A product-copying theory focuses on the implementation the company plans to sell. A portfolio theory asks what alternatives a competitor is likely to adopt. Claims may be directed to the core architecture, alternative allocations of functionality, interfaces, workflows, manufacturing techniques, performance improvements, security layers, and downstream uses. The objective is not to patent every conceivable variation. It is to identify the small number of technically and commercially realistic routes by which a rival could capture the same value.

That is the difference between a portfolio “moat” and a patent count. Multiple patents directed to nearly identical narrow features may produce an impressive total while leaving obvious substitutes untouched. Conversely, a smaller set of claims positioned across different technical layers may make design-around slower, costlier, or less attractive. The portfolio should be evaluated against the competitor’s choices, not simply against the company’s filing history.

B.                 Patent Protection Versus Defensive Publication and Trade Secrecy

Sometimes the company’s objective is merely to prevent a later filer from obtaining a patent on the same technology. A published patent application can become prior art under 35 U.S.C. § 102(a)(2), but a less expensive defensive publication may accomplish the blocking objective without years of prosecution and maintenance fees. A deliberately public and sufficiently informative disclosure may become prior art under § 102(a)(1), but it creates no exclusionary right and can jeopardize the publisher’s own patent options, particularly outside the United States. 35 U.S.C. § 102(a)(1), (b)(1); MPEP § 2128(I) (9th ed. Rev. 01.2024); In re Wyer, 655 F.2d 221, 226 (C.C.P.A. 1981).

Trade-secret protection points in the opposite direction. It can endure as long as secrecy and reasonable protective measures are maintained. 18 U.S.C. § 1839(3). Patent and trade-secret law are complementary, not mutually hostile, systems, but trade-secret law does not prevent lawful independent invention or reverse engineering. Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 476, 489–91 (1974). A process that cannot be reverse engineered may be a strong trade-secret candidate. A customer-visible feature that a competitor can inspect may not be. The correct choice depends on the business objective and the information’s practical secrecy, not on a presumption that patenting is always superior.

VI.            Standards, Interoperability, and Ecosystem Influence

Patents can become especially important when technology is incorporated into a widely adopted standard. A patent that is actually essential to practicing the standard may be relevant to an industry far larger than the patent owner’s product share. Participation in standard development can also give a company insight into technical direction and a platform for contributing technology that becomes interoperable across an ecosystem.

That opportunity carries constraints. Standard-setting organizations may require disclosure and commitments to license standard-essential patents on fair, reasonable, and nondiscriminatory terms. Depending on the governing SSO documents and contract law, courts have treated particular RAND or FRAND commitments as enforceable contractual obligations and have adapted damages analysis to account for the standard-setting context. Microsoft Corp. v. Motorola, Inc., 795 F.3d 1024, 1031–32 (9th Cir. 2015); Ericsson, Inc. v. D-Link Sys., Inc., 773 F.3d 1201, 1230–35 (Fed. Cir. 2014). Patent pools and collective licensing platforms can reduce the transaction cost of obtaining complementary rights, but their structure also must account for competition-law concerns. See U.S. Dep’t of Just. & Fed. Trade Comm’n, Antitrust Guidelines for the Licensing of Intellectual Property § 5.5 (2017) (nonbinding agency enforcement guidance).

For many participants, royalties are only part of the value. A standards portfolio can support access to other participants’ patents, cross-licenses, ecosystem influence, and a reputation for contributing foundational technology. The company may obtain a patent not because it expects to exclude every implementer, but because it expects the patent to affect the terms on which the entire industry obtains access.

Standards are not the only ecosystem use. Tesla publicly pledged not to initiate patent lawsuits against parties acting in good faith while using its electric-vehicle technology, explaining that a common, rapidly evolving platform could advance the market. Tesla, Inc., Patent Pledge, https://www.tesla.com/legal/additional-resources (last visited July 17, 2026). Toyota likewise offered royalty-free licenses through 2030 to nearly 24,000 patents concerning vehicle electrification technologies and offered technical support to accelerate adoption. Toyota Motor Corp., Toyota Promotes Global Vehicle Electrification by Providing Nearly 24,000 Licenses Royalty-Free (Apr. 3, 2019), https://global.toyota/en/newsroom/corporate/27512455.html. In both instances, the portfolio could be used to attract complementors and enlarge the relevant market rather than to maximize immediate exclusion.

VII.         Licensing, Monetization, and the Reuse of Non-Core Technology

Licensing is the most visible non-product use of a patent, but it takes several forms. A company may license competitors, suppliers, customers, or participants in adjacent markets. It may preserve exclusivity for its core product while granting rights for different fields of use. It may bundle patents with know-how, software, data rights, technical support, or trademarks. It may contribute patents to a pool. Or it may sell a family that no longer aligns with its business.

For some large companies, licensing is a central operating model. Qualcomm tells investors that its licensing segment grants rights under a portfolio that includes standards-essential and non-essential patents, and it warns that maintaining patents applicable to current and future standards, products, and services is critical to future licensing revenue. Its licensing segment generated $5.582 billion of revenue and $4.043 billion of earnings before taxes in fiscal 2025. QUALCOMM Inc., Annual Report (Form 10-K) 9–10, 23, 38, 41 (Nov. 5, 2025). IBM likewise reports income from licensing and selling internally developed patents and other intellectual property. International Business Machines Corp., 2025 Annual Report 22, 53 (2026).

Other companies use licensing selectively. Research performed for one market may solve a problem in another market that the company has no intention of entering. A license can turn that dormant technical capability into revenue without requiring a new operating business. The patent’s transferability separates the invention from the particular team or product that created it. Occasionally that separability produces a major transaction: AOL sold approximately 800 patents and related patent applications to Microsoft and granted Microsoft a nonexclusive license to AOL’s retained patent portfolio for aggregate cash proceeds of $1.056 billion. AOL Inc., Annual Report (Form 10-K) 89 (Feb. 27, 2015).

Sales of non-core patents demand broader judgment. A sale may recover value from a discontinued program, simplify a portfolio, or supply assets to a company better positioned to commercialize them. A sale to an assertion-focused entity may also create downstream litigation against customers, suppliers, partners, or members of an existing cross-license network. License-back rights, covenants, existing encumbrances, change-of-control clauses, reputational effects, and competition concerns may matter as much as price. Monetization is not merely the act of finding the highest bidder; it is the allocation of future enforcement risk.

VIII.       Valuation, Financing, and Corporate Transactions

A.                 Patents as Information for Investors

Patents can communicate information that outsiders cannot obtain easily from a product demonstration or a research budget. They disclose inventors, filing data, technical subject matter, and often recorded assignee information, although public ownership records may be incomplete or stale; issued claims eventually add information about legal scope. That visibility can reduce information asymmetry. Clarisa Long’s “patent signals” account explains that the informational function of a patent can, in some circumstances, be more valuable to the owner than the substantive exclusionary right. Clarisa Long, Patent Signals, 69 U. Chi. L. Rev. 625, 636–41, 647–55 (2002).

Empirical work also has found a relationship between firms’ market value and citation-weighted patent measures, while emphasizing that citations and other quality indicators carry information that raw counts omit. Bronwyn H. Hall, Adam Jaffe & Manuel Trajtenberg, Market Value and Patent Citations, 36 RAND J. Econ. 16, 16–18, 31–34 (2005). The inference should be modest. A patent does not prove commercial success, and an issued claim may cover technology that never reaches a market. But in a field where investors cannot directly evaluate technical depth, a coherent portfolio can provide evidence that the company has produced identifiable technical assets.

B.                 Mergers, Acquisitions, and Divestitures

Patents can increase transaction value by protecting a target’s revenue, filling an acquirer’s portfolio gap, creating licensing options, or reducing the risk that key employees can leave and recreate the same product for a competitor. They can also reveal defects. Missing assignments, inconsistent inventor agreements, joint ownership, government rights, liens, license grants, covenants not to sue, standards commitments, and prosecution problems may materially change the bargain.

Google’s acquisition of Motorola Mobility provides a particularly clear example of portfolio-driven transaction strategy. Google publicly stated that the acquisition would strengthen its patent portfolio and help protect Android. Larry Page, Supercharging Android: Google to Acquire Motorola Mobility, Google Pub. Pol’y Blog (Aug. 15, 2011), https://publicpolicy.googleblog.com/2011/08/supercharging-android-google-to-acquire.html. Motorola’s proxy materials described diligence involving approximately 24,000 patents and applications across wireless and related technologies. Motorola Mobility Holdings, Inc., Definitive Proxy Statement (Schedule 14A) 27–30 (Oct. 14, 2011). Google later sold the Motorola Mobility business to Lenovo while retaining most of the patent portfolio and granting Lenovo a license, illustrating that the patents supplied strategic value separable from the operating assets. Google Inc., Annual Report (Form 10-K) 30 (Feb. 12, 2015).

Ownership diligence matters because patent rights initially vest in inventors, and an employer’s expectation that it funded the work does not substitute for a written assignment. Bd. of Trs. of Leland Stanford Junior Univ. v. Roche Molecular Sys., Inc., 563 U.S. 776, 785–86 (2011). Applications, patents, and interests in them are assignable by a written instrument; recordation within three months or before a later purchase or mortgage protects against a qualifying later purchaser or mortgagee for value without notice. 35 U.S.C. § 261. USPTO recordation is ministerial and does not adjudicate the instrument’s validity or resolve chain of title. MPEP §§ 301(II), 313 (9th ed. Rev. 01.2024).

C.                 Collateral and Restructuring Value

Patents can be pledged as collateral. The USPTO’s Patent Assignment Dataset identifies recorded security-interest agreements in which patents or applications secure debt. Alan C. Marco, Amanda F. Myers & Stuart J.H. Graham, The USPTO Patent Assignment Dataset: Descriptions and Analysis 10–12 (USPTO Econ. Working Paper No. 2015-2, 2015). In one leading decision, the Ninth Circuit held that an Article 9 filing perfected a patent security interest against a later lien creditor and that the Patent Act did not preempt that state-law regime; § 261 separately addresses certain later purchasers and mortgagees. In re Cybernetic Servs., Inc., 252 F.3d 1039, 1057–60 (9th Cir. 2001). USPTO recordation does not determine the legal effect of the recorded instrument, and the decision should not be treated as a universal filing prescription for every transaction. MPEP § 313 (9th ed. Rev. 01.2024).

Patents and licenses may also retain value in restructuring. When a debtor is the licensor under an executory intellectual-property license and the trustee or debtor in possession rejects the contract, § 365(n) permits the licensee to elect to retain specified intellectual-property and exclusivity rights for the contract term and any extension the licensee may exercise as of right, subject to continuing royalty and waiver provisions. 11 U.S.C. § 365(n)(1)–(3); see also 11 U.S.C. § 101(35A) (including patents within the definition of intellectual property). The election is not a general rule that every license survives bankruptcy unchanged. The practical value of a patent as collateral or a separable asset, moreover, depends on whether it can be used without the company’s people, data, software, know-how, regulatory approvals, or manufacturing capability. A patent that cannot travel with the complementary assets may have little standalone value.

IX.             Signaling Technological Capability

Signaling is broader than formal investor communication or advertising. Published applications and issued patents can tell competitors, prospective employees, universities, and potential partners where the company is building expertise. A portfolio concentrated in an emerging technology may suggest a long-term commitment before revenue appears. It can attract collaboration proposals, encourage a competitor to design around, or cause a potential licensee to approach the owner.

The signal can be useful even when observers cannot value each claim. Filing is costly, requires the company to identify inventors and technical subject matter, and ordinarily exposes the application to examination before a patent issues. Those features can make the signal more credible than a bare statement that the company is “innovative.” Long, supra, at 647–55. But the signal is noisy. Companies can acquire patents, pursue narrow claims, continue related applications, or file the same invention in many countries. Sophisticated observers therefore look beyond the headline number to relevance, ownership history, family structure, claim scope, citations, remaining life, and alignment with products.

Publication also informs competitors. A portfolio may reveal technical direction, product priorities, and engineering alternatives earlier than the company would disclose them voluntarily. The signaling value of disclosure must therefore be balanced against secrecy and timing.

X.                Attracting, Retaining, and Motivating Technical Talent

A.                 Recognizing and Retaining Inventors

Patent programs can recognize engineers and scientists in a durable public record. Inventor awards, internal ceremonies, and portfolio milestones may reinforce a culture in which employees identify and disclose technical advances. Empirical studies have treated enhancement of the firm’s or employees’ reputation and internal inventor incentives as identifiable patenting motives. Cohen, Nelson & Walsh, supra, at 17–18; Blind et al., supra, at 658–66.

B.                 Recruitment and Retention

A visible inventor culture can help recruit technical personnel who want to work on advanced technology and receive recognition for their contributions. IBM’s “Master Inventor” program, for example, emphasizes sustained invention, portfolio contribution, mentoring, and technical leadership, turning patent participation into both an internal career marker and an external employment signal. IBM, Introducing 7 of IBM’s Masters of Invention, IBM Newsroom, https://newsroom.ibm.com/Introducing-7-of-IBMs-Masters-of-Invention (last visited July 17, 2026).

C.                 Risks of Incentive Design

The incentive must be designed carefully. Rewards based solely on filing or issuance totals can encourage low-value disclosures, fragmented applications, and claims disconnected from commercial need. Recognition is better tied to technical contribution, strategic relevance, and useful claim coverage than to a numerical quota.

XI.             Marketing Innovation and Technological Leadership

A.                 Patent Counts as a Corporate Narrative

Patent totals are unusually convenient marketing facts. They are numerical, public, superficially comparable, and associated in the public mind with invention. An investor-relations team can say that Company X holds more patents in a technology than Company Y. A sales team can point to the portfolio as evidence that the company develops proprietary technology rather than merely repackaging third-party components. A regional business unit can use local filings and named inventors to support a claim that it is an innovation leader in a particular country.

That use is neither hypothetical nor confined to small companies. IBM publicly emphasized a WIPO report identifying it as the global leader in artificial-intelligence patent applications and connected the ranking to work in natural-language processing, speech, computer vision, and machine learning. IBM, IBM Named AI Patent Leader in First Ever Global Report (Jan. 31, 2019), https://newsroom.ibm.com/index.php?item=30896&s=20317. Canon’s 2026 announcement emphasized both its seventh-place ranking in U.S. patent grants and its forty-two consecutive years in the top ten of that U.S.-grant ranking. Canon Inc., Canon Ranked Seventh in U.S. Patent Ranking, Now in the Top 10 for 42 Years Running (Jan. 16, 2026), https://global.canon/en/news/2026/20260116-2.html. These announcements show patents operating as communications assets, not merely litigation assets.

The commercial inference is intuitive: more patents may suggest deeper expertise, sustained research spending, a larger technical workforce, more options for future products, or a stronger barrier to imitation. The inference is not self-proving. The marketing task is to convert the count into a credible account of why the portfolio matters.

B.                 Investor Relations and the Wall Street Comparison

Investors evaluating an emerging technology often face severe information asymmetry. Management knows the research program; investors see forecasts and selected demonstrations. Patent data can supply an observable indicator. A company may compare its number of artificial-intelligence, quantum, semiconductor, battery, medical-device, or wireless patent families with a competitor’s and argue that it is better positioned for the market that follows.

The strongest investor narrative does more than announce a total. It explains whether the portfolio covers foundational architecture, commercially important improvements, multiple layers of a technology stack, or standards contributions. It connects patent growth to research priorities and identifies how the rights may support products, licensing, partnerships, or defensive leverage. Qualcomm’s public disclosure is an example of that connection: it does not merely report owning patents; it tells investors that portfolio evolution in 5G and next-generation technologies is critical to licensing revenue. QUALCOMM Inc., supra, at 23.

Patent counts should nevertheless be treated as indicators, not valuation formulas. Citation-weighted measures, family breadth, renewal decisions, claim-product alignment, and remaining term can convey information that a gross document count cannot. Hall, Jaffe & Trajtenberg, supra, at 31–34. Even those measures are imperfect. A highly cited patent may be cited because it is old or occupies a crowded field; a young foundational patent may not yet have accumulated citations. The appropriate investor message is that the portfolio supports a business thesis—not that the count conclusively proves enterprise value.

IBM’s later change in strategy supplies a useful counterexample to its own long-running leadership campaign. IBM disclosed in 2023 that it had decided in 2020 to stop pursuing numerical U.S. patent leadership and instead emphasize selective protection of high-quality advances. Darío Gil, How Do You Measure Innovation?, IBM Rsch. (Jan. 9, 2023), https://research.ibm.com/blog/Ibm-innovation-2022. The change did not make the earlier patents worthless. It showed that the metric serving the company’s innovation narrative can change as business strategy changes.

Public-company communications require particular discipline. If used in securities communications, a patent metric that is materially false or misleading may create Rule 10b-5 exposure when the other elements—including the required scienter and connection to a securities transaction—are present; methodological imprecision is not automatically securities fraud. 17 C.F.R. § 240.10b-5(b) (2026). A statement that the company owns “the largest AI patent portfolio” may require qualification if the ranking counts pending applications, includes acquired patents, treats foreign counterparts as separate inventions, or depends on a disputed technology classification. The patent team should be involved before portfolio statistics appear in an earnings presentation, annual report, or investor deck.

C.                 Sales, Product Marketing, and Competitive Differentiation

Sales teams can use patents to transform an unseen engineering difference into a comprehensible commercial message. “Protected by twenty-seven patents” suggests that the feature is proprietary, difficult to reproduce, and the product of sustained investment. For an enterprise customer, the portfolio may also suggest that the vendor has committed to the technology and will continue developing it.

That message can matter in requests for proposals, product launches, trade shows, partner presentations, and head-to-head sales comparisons. A sales team may use a defined ranking—such as more active patent families in the relevant field than named competitors—to substantiate a category-leadership claim, subject to the methodology caveats below. Dyson, for example, markets the engineering investment behind its products by emphasizing “pioneering and patented technology.” Dyson Ltd., Only a Dyson Works Like a Dyson: The Engineering Behind Dyson Machines (June 26, 2020), https://www.dyson.com/discover/innovation/behind-the-invention/only-a-dyson-works-like-a-dyson. Patent-based differentiation can be especially useful when competing products appear similar at the interface but differ in underlying security, manufacturing, performance, or system architecture. A product-specific claim is most credible when the cited patents actually cover the advertised feature. Patents that merely share a broad classification or mention the same field provide a weaker foundation.

Product marketing also intersects with marking law. Marking a patented article can affect the availability of pre-suit damages, and virtual marking may be used when statutory requirements are satisfied. 35 U.S.C. § 287(a); Arctic Cat Inc. v. Bombardier Recreational Prods. Inc., 876 F.3d 1350, 1366–68 (Fed. Cir. 2017). Conversely, falsely using “patent pending” in advertising for the purpose of deceiving the public falls within the false-marking statute. 35 U.S.C. § 292(a). Only the United States may recover the statutory penalty, while a private plaintiff must have suffered competitive injury to seek compensatory damages. Id. § 292(a)–(b). Marking with an expired patent that once covered the product is not a false-marking violation, although removing stale references may improve clarity. Id. § 292(c). Marketing, product, and patent teams should therefore maintain a process for adding newly issued patents, reviewing expired or inapplicable references, and distinguishing issued rights from pending applications.

D.                 Marketing National and Regional Innovation Leadership

A multinational company may want to be perceived not only as a global innovator, but as an innovation leader within a particular country. That positioning can help recruit engineers, build government relationships, obtain research partnerships, support local procurement, and demonstrate commitment to a market.

Samsung’s Indian research organization, for example, publicized an innovation award by pointing to a portfolio exceeding 11,000 filings and an internal innovation culture. Samsung R&D Inst. India—Bangalore, Samsung R&D Institute India, Bangalore Takes Home 4 Awards at the Zinnov Confluence 2025; Recognized as a “Great Place to Innovate” (Aug. 1, 2025), https://news.samsung.com/in/samsung-r-recognized-as-a-great-place-to-innovate. Huawei has described leading patent-application positions in Japan, South Korea, Vietnam, and India while connecting those positions to regional investment, licensing, and technical development; it also describes more than 55,000 active patents granted in China as making it China’s leading patent holder. Huawei Techs. Co., Innovation and Intellectual Property, https://www.huawei.com/en/ipr (last visited July 17, 2026); Huawei, Huawei IPR Vision and Strategy, https://www.huawei.com/en/media-center/transform/04/huawei-ipr-vision-and-strategy (last visited July 17, 2026).

Those narratives require careful definition. A patent filed in India does not necessarily identify an Indian inventor. A patent granted by the Japan Patent Office does not establish that the underlying research occurred in Japan. A patent assigned to a local subsidiary may have been developed elsewhere, while a locally invented technology may be owned centrally by a foreign parent. Bibliographic data do not by themselves prove the actual R&D location or the current employment of named inventors. “Leading filer in a country,” “leading local inventor,” and “company with the largest locally owned portfolio” are different claims.

The intended audience determines which measure matters. A government focused on local research employment may care about inventor residence and laboratory investment. A customer may care about patents enforceable in the country. An investor may care about worldwide families owned by the consolidated enterprise. A recruiting campaign may focus on patents naming employees at the local research center. The marketing claim should match the fact being measured.

E.                  Rankings, Awards, and Earned Media

Portfolio statistics can generate third-party rankings, awards, press coverage, and milestone announcements. A company can publicize its thousandth patent, a top ranking in a technology class, or the number of employees named as inventors. That coverage creates a reputational return even if none of the identified patents is separately licensed.

Third-party attribution improves credibility but does not eliminate methodological questions. Rankings may rely on patent grants during one year, all active patents, applications, simple families, extended families, assignee names, ultimate-parent ownership, technical classifications, declared standard-essential patents, or an evaluator’s own essentiality analysis. Samsung’s 5G announcement, for example, accurately identified the outside study and the metric—share of 5G standard-essential patents—rather than presenting an undefined claim to be the most innovative company overall. Samsung Elecs., Samsung Extends Leadership in 5G Patents (Mar. 10, 2021), https://news.samsung.com/us/samsung-extends-leadership-5g-patents.

XII.          Public-Policy, Regulatory, and Government-Contracting Uses

Patents can support applications for grants, public-private research partnerships, procurement opportunities, and economic-development incentives by documenting technical activity and identifying local inventors. In regulated fields, patents can complement—but should not be confused with—regulatory approval, data exclusivity, market authorization, or reimbursement. Each protection has a different trigger, scope, and duration.

Government-funded inventions require additional care, particularly when discussing large companies. Section 202 directly addresses small businesses and nonprofit organizations. 35 U.S.C. § 202(a), (c)(1)–(5). Section 210(c), executive orders, and agency funding clauses extend related title-retention policy and safeguards to other contractors. For a large for-profit contractor, the operative patent-rights clause—not § 202 standing alone—determines title-retention and compliance duties. Depending on that clause, the contractor may face disclosure, election, filing, employee-assignment, utilization-reporting, government-license, march-in, and domestic-manufacturing conditions. 35 U.S.C. §§ 203(a), 210(c); Exec. Order No. 12,591, § 1(b)(4), 3 C.F.R. 220, 221 (1988); Exec. Order No. 12,618, § 1, 3 C.F.R. 262 (1988); 37 C.F.R. § 401.14(a)(2)–(3), (a)(8), (b)–(c), (f)(2), (h)–(j) (2026). The manufacturing term in § 401.14(i) concerns specified exclusive rights to use or sell in the United States and may be waived; it is not a blanket domestic-manufacturing mandate for every corporate patent. Those conditions can affect licensing, assignment, diligence, and transaction value. A patent may help demonstrate successful research output while carrying restrictions that a purely privately funded patent does not.

XIII.       Costs and Risks That the Business Case Must Absorb

Every patent strategy carries costs beyond the initial application. Prosecution, continuations, foreign associates, translations, validation, annuities, maintenance fees, recordation, claim mapping, and periodic review continue for years. Public disclosure can teach competitors and reveal product direction. Narrowing amendments made for patentability may trigger prosecution-history estoppel and limit the doctrine of equivalents. Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 733–34 (2002). Clear and unmistakable prosecution disclaimer also may narrow claim construction. Omega Eng’g, Inc. v. Raytek Corp., 334 F.3d 1314, 1323–26 (Fed. Cir. 2003).

Ownership errors can impair standing or transaction value. Standards commitments and existing licenses can limit enforcement options. Government rights can affect assignment and manufacturing. Product marking can become inaccurate. A later sale can create conflict with customers or partners. Patents that are never reviewed may remain on the books after their commercial rationale disappears.

There is also opportunity cost. Money spent obtaining ten weak patents cannot be spent drafting two stronger applications, conducting freedom-to-operate analysis, maintaining trade-secret controls, acquiring a blocking patent, or publishing defensively. A large company can afford more patents than a startup, but scale does not eliminate the need to allocate resources.

XIV.      Conclusion: The Patent as a Corporate Decision Asset

A patent that is never asserted may still be successful. It may have contributed to a lawsuit that was never filed, a cross-license negotiated without public conflict, a product path preserved during uncertainty, a partner willing to collaborate, an acquisition completed at a higher price, or an investor persuaded that the company possesses meaningful technical depth. It may have helped a sales team differentiate a product or allowed a multinational company to demonstrate innovation within a strategically important country.

Those outcomes do not change what the Patent Act grants. The legal right remains a limited right to exclude. They do change how corporate value should be measured. Litigation and royalty receipts are visible endpoints, but much of a portfolio’s work occurs earlier and more quietly, by changing incentives, information, and bargaining positions.

The right question is therefore not whether every patent will be enforced. It is whether the patent is likely to change a commercially important decision in a way that justifies its cost. Large-company portfolios become more defensible—and more valuable—when each family has an intended business function, that function shapes prosecution and communication, and the company is willing to abandon the asset when the function no longer exists.